Clinical Trials on B-cell Malignancy in Belgium

Total 1473 results

GlaxoSmithKline

Completed

Long-term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Mth Schedule in Healthy Adults

Hepatitis B | Hepatitis A

Belgium
GlaxoSmithKline

Completed

Comparison of Monodose and Multidose Presentations of GSK Biologicals' Hepatitis B Vaccine in Terms of Immune Response

Hepatitis B

Belgium
GlaxoSmithKline

Completed

Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine (2 Doses), and of Engerix™-B (3 Doses) in Healthy Adults

Hepatitis B

Belgium
GlaxoSmithKline

Completed

Immunogenicity & Reactogenicity of HBV-MPL Vaccine and Engerix™-B in Healthy Adults Following 2 Different Schedules

Hepatitis B

Belgium
GlaxoSmithKline

Completed

Immunogenicity & Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine With Different Adjuvants

Hepatitis B

Belgium
Novartis Pharmaceuticals

Terminated

Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia (COMPLEMENT 1)

Leukaemia, Lymphocytic, Chronic

Spain, United States, Belgium, India, United Kingdom, Netherlands, Czechia, Germany, Greece, Italy, Russian Federation, Sweden, Canada, Ireland, Poland, France, Brazil
GlaxoSmithKline

Completed

Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Adults (15-40 Yrs).

Hepatitis B

Denmark, Belgium
Amgen

Terminated

Safety Study of AMG 228 to Treat Solid Tumors

Melanoma | Cancer | Colorectal Cancer | Advanced Solid Tumors | Squamous Cell Carcinoma of the Head and Neck | Non-small Cell Lung Cancer | Oncology | Tumors | Advanced Malignancy | Oncology Patients | Transitional Cell Carinoma of Bladder

Belgium, France, United States, Germany, Australia
GlaxoSmithKline
Region of Wallonia; Public Private Partnership with Institute for Medical Immunology...

Completed

Development of Read-outs in Healthy, Hepatitis B Virus Naive Adults Vaccinated With the Hepatitis B Surface Antigen (HBsAg) in Combination With a GlaxoSmithKline (GSK) Biologicals' Adjuvant System

Hepatitis B

Belgium
Jules Bordet Institute

Recruiting

Molecular Imaging of FAP Expressing Cancer-associated Fibroblasts in NSCLC Treated With Immune-checkpoint Inhibitors (LIFE)

Non Small Cell Lung Cancer

Belgium
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (RESONATE™)

Relapsed or Refractory Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Australia, Austria, Belgium, France, Ireland, Italy, Poland, Spain, United Kingdom
University Hospital, Antwerp
Universiteit Antwerpen; Belgian Cancer Registry

Enrolling by invitation

Implementation of Lung Cancer Screening in the First Line Zone of ZORA (Flanders), Using a Low Dose CT-scan (ZORALCS)

Smoking Cessation | Lung Cancer | Lung Cancer, Nonsmall Cell | Lung Cancer, Small Cell

Belgium
Nektar Therapeutics

Completed

An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies

Malignant Solid Tumor

United States, Belgium
Universitair Ziekenhuis Brussel

Unknown

Anaesthesia and mHealth

Anesthesia | Mobile Applications | Cell Phone

Belgium
GlaxoSmithKline

Completed

Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Month Schedule

Hepatitis B | Hepatitis A

Belgium
University Hospital, Ghent

Completed

A Feasibility Study On Continuous Adaptive [18f]Fdg-Pet-Guided Radiotherapy For Head and Neck Cancer

Squamous Cell Carcinoma

Belgium
University Hospital, Ghent
Erasmus Medical Center

Enrolling by invitation

HRQoL Keratinocyte Carcinomas

Actinic Keratoses | Basal Cell Carcinoma | Squamous Cell Carcinoma

Belgium, Netherlands
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Australia, Belgium, Canada, China, Czechia, Ireland, Israel, Italy, New Zealand, Poland, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
University Hospital, Ghent
Nationaal Kankerplan

Terminated

Prediction of the Effectiveness of Hypofractionated Radiation Therapy in Early Stage Lung Cancer by Bio-imaging and Biomarkers (PEARL-2)

Inoperable Early Stage Non-small Cell Lung Cancer

Belgium
Cliniques universitaires Saint-Luc- Université...
Centre Georges Francois Leclerc

Completed

Simultaneous Integrated Boost (SIB)- IMRT

Carcinoma, Squamous Cell

Belgium
University Hospital, Ghent
University Ghent; Kom Op Tegen Kanker

Active, not recruiting

MIDRIXNEO-LUNG Dendritic Cell Vaccine in Patients With Non-small Cell Lung Cancer (MIDRIXNEO)

Non-small Cell Lung Cancer

Belgium
Ethicon Endo-Surgery

Completed

Harmonic ACE®+7 Shears in Laparoscopic Colectomy

Benign or Malignant Disease Indicated for Colectomy

United States, Belgium, United Kingdom
GlaxoSmithKline

Completed

Long-term Persistence Study in Healthy Adults Previously Vaccinated With Twinrix Adult

Hepatitis B | Hepatitis A

Belgium
GlaxoSmithKline

Completed

Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,6 Month Schedule

Hepatitis B | Hepatitis A

Belgium
GlaxoSmithKline

Completed

Evaluation of Immunogenicity, Reactogenicity and Safety of HBV-MPL Vaccine vs Engerix™-B, in Haemodialysis Patients

Hepatitis B

Belgium
GlaxoSmithKline

Completed

Immunogenicity and Reactogenicity of MPL Adjuvanted Recombinant Hepatitis B- Vaccine and Engerix™-B in Adult Non-Responders

Hepatitis B

Belgium
University Hospital, Ghent
University Ghent; Kom Op Tegen Kanker

Active, not recruiting

MIDRIX4-LUNG Dendritic Cell Vaccine in Patients With Metastatic Non-small Cell Lung Cancer (MIDRIX4-LUNG)

Non-small Cell Lung Cancer Metastatic

Belgium
Jules Bordet Institute
AstraZeneca; Institut Curie

Active, not recruiting

Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer: (Neo-CheckRay)

Luminal B

France, Belgium
European Organisation for Research and Treatment...
Boehringer Ingelheim

Completed

Neoadjuvant Afatinib Window Study in Squamous Cell Carcinoma of the Head and Neck

Carcinoma, Squamous Cell of Head and Neck

Belgium, Italy
University Hospital, Antwerp
Agentschap voor Innovatie door Wetenschap en Technologie

Completed

Combined FDG PET/CT Imaging in Response Evaluation After Radiochemotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) (ECLYPS)

Locally Advanced Squamous Cell Carcinoma of the Head and Neck Region

Belgium, Netherlands
Juno Therapeutics, Inc., a Bristol-Myers Squibb...
Celgene Corporation

Withdrawn

A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

Leukemia, Lymphocytic, Chronic, B-Cell

United States, Austria, Belgium, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, United Kingdom
Universitaire Ziekenhuizen KU Leuven

Recruiting

LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib (LAT-FLOSI)

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

Belgium
Janssen Research & Development, LLC
Pharmacyclics LLC.

Active, not recruiting

A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (GLOW)

Leukemia, Lymphocytic, Chronic, B-Cell

Canada, Belgium, Netherlands, Spain, Israel, United States, Czechia, Denmark, United Kingdom, France, Russian Federation, Turkey, Poland, Sweden
Hanane EL KENZ

Completed

Transfusion in Sickle Cell Disease: Screening of Sickle Cell Disease Trait in Blood Donors

Sickle Cell Disease | Sickle Cell Trait

Belgium
Universitaire Ziekenhuizen KU Leuven

Completed

Endobronchial Valves in Persistent Air Leak

Malignant Neoplasm of Lung

Belgium
Jules Bordet Institute

Completed

The Jules Bordet Institute Molecular Profiling Program Feasibility Trial (PRECISION-F)

Metastatic Melanoma | Colorectal Cancer Metastatic | Metastatic Non-Small Cell Lung Carcinoma

Belgium
Universitaire Ziekenhuizen KU Leuven
Fund for Scientific Research, Flanders, Belgium

Unknown

Assessment of Hepatitis B Virus Intra-host Population and Host-specific Immune Marker Diversity

End Stage Liver Disease | Hepatitis B | Carcinoma, Hepatocellular | Hepatitis B, Chronic

Belgium
Gilead Sciences

Terminated

Utilization and Efficacy of Tenofovir DF in Adolescents With Chronic Hepatitis B Virus Infection

Hepatitis B

Spain, Italy, United Kingdom, Romania, Belgium, France, Greece
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, France, Poland, Belgium, Germany, Spain, Argentina, Colombia, Israel, Portugal, Russian Federation, Turkey, Ukraine, Canada, Greece, Sweden, Korea, Republic of, United Kingdom, Brazil, Mexico, Czechia
Hasselt University

Unknown

Hepatitis B Prevalence in the Turkish Population Living in Middle Limburg (HBVTR)

Hepatitis B

Belgium
M.D. Anderson Cancer Center

Completed

Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix

Adenocarcinoma | Cervical Cancer | Cervical Squamous Cell Carcinoma | Locally Advanced Malignant Neoplasm | Adenosquamous Carcinoma

United States, Belgium
European Organisation for Research and Treatment...

Active, not recruiting

Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM

Malignant Pleural Mesothelioma

Belgium, Netherlands
Universitair Ziekenhuis Brussel

Completed

Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Mesenchymal Stem Cells

Allogeneic Stem Cell Transplantation

Belgium
University Hospital, Ghent
Merck Sharp & Dohme LLC

Completed

A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma. (MesoMab)

Cancer

Belgium, Netherlands
Universitair Ziekenhuis Brussel

Recruiting

The Safety and Feasibility of Costal Bone Marrow Aspiration During Thoracic Surgery

Non Small Cell Lung Cancer

Belgium
Bayer

Completed

A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ® (PONDIAC)

Carcinoma, Renal Cell | Carcinoma, Renal Cell (Advanced)

Belgium
Vrije Universiteit Brussel
Kom Op Tegen Kanker

Unknown

Effects of VNS on RT-induced Inflammation and Prognosis of Patients With NSCLC

Lung Cancer, Non-small Cell

Belgium
Centre Hospitalier Universitaire de Liege

Recruiting

PROspective Trial on EOsinophilia in Non-Small Cell Lung Cancer (NSCLC). (PROTEON)

Non-small Cell Lung Cancer

Belgium
Incyte Corporation

Active, not recruiting

A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (topMIND)

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

United States, Spain, France, Italy, Belgium, Germany, Austria
SecuraBio

Completed

A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

Belgium, France, Italy, Spain, United States, Austria, New Zealand, Hungary, United Kingdom, Australia, Germany

Clinical Trials on B-cell Malignancy in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations